Table 5.
Cost, effect, and cost-effectiveness (cost per major CV event avoided) (£sterling, 2005/06 prices)
| Rosuvastatin vs. placebo | Point estimate (95% CI) | ICER (95% CI)a |
|---|---|---|
| Incremental effectb | 0.164 (0.075, 0.254) | |
| Incremental total cost (CV hospitalization, procedure and Tx costs) | £303 (138, 467) | £1840 (562, 6028) |
| Incremental total cost, including non-CV hospitalization | £289 (95, 484) | £1759 (398, 6092) |
| Incremental total cost, including monitoring visits | £343 (179, 509) | £2090 (729, 6576) |
| Incremental total cost, excluding cardiac transplantations | £328 (176, 481) | £1987 (705, 6230) |
CV, cardiovascular; Tx, treatment; ICER incremental cost-effectiveness ratio.
a95% confidence interval for the ICER estimated using Fieller's Theorem.
bThis is the difference between an average of 1.204 major CV events per patient in the placebo group and 1.039 in the rosuvastatin group, see Table 2.